ESTRADIOL; LEVONORGESTREL - Generic Drug Details

What are the generic drug sources for estradiol; levonorgestrel and what is the scope of freedom to operate?

Estradiol; levonorgestrel is the generic ingredient in one branded drug marketed by Bayer Hlthcare and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for ESTRADIOL; LEVONORGESTREL

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	3
Clinical Trials:	84
Patent Applications:	107
DailyMed Link:	ESTRADIOL; LEVONORGESTREL at DailyMed

Recent Clinical Trials for ESTRADIOL; LEVONORGESTREL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
HIV Prevention Trials Network	PHASE2
National Institute of Allergy and Infectious Diseases (NIAID)	PHASE2
Fudan University	PHASE2

See all ESTRADIOL; LEVONORGESTREL clinical trials

Pharmacology for ESTRADIOL; LEVONORGESTREL

Drug Class	Estrogen Progestin Progestin-containing Intrauterine System
Mechanism of Action	Estrogen Receptor Agonists
Physiological Effect	Inhibit Ovum Fertilization

Anatomical Therapeutic Chemical (ATC) Classes for ESTRADIOL; LEVONORGESTREL

G03AC	Progestogens
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03AD	Emergency contraceptives
G03A	HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

G03CA	Natural and semisynthetic estrogens, plain
G03C	ESTROGENS
G03	SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G	Genito-urinary system and sex hormones

US Patents and Regulatory Information for ESTRADIOL; LEVONORGESTREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Hlthcare	CLIMARA PRO	estradiol; levonorgestrel	FILM, EXTENDED RELEASE;TRANSDERMAL	021258-001	Nov 21, 2003		RX	Yes	Yes

Expired US Patents for ESTRADIOL; LEVONORGESTREL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Hlthcare	CLIMARA PRO	estradiol; levonorgestrel	FILM, EXTENDED RELEASE;TRANSDERMAL	021258-001	Nov 21, 2003	5,252,334
Bayer Hlthcare	CLIMARA PRO	estradiol; levonorgestrel	FILM, EXTENDED RELEASE;TRANSDERMAL	021258-001	Nov 21, 2003	5,393,529
Bayer Hlthcare	CLIMARA PRO	estradiol; levonorgestrel	FILM, EXTENDED RELEASE;TRANSDERMAL	021258-001	Nov 21, 2003	5,770,219
Bayer Hlthcare	CLIMARA PRO	estradiol; levonorgestrel	FILM, EXTENDED RELEASE;TRANSDERMAL	021258-001	Nov 21, 2003	5,676,968

Market Dynamics and Financial Trajectory for Estradiol; Levonorgestrel

Last updated: February 14, 2026

Overview

The combination of estradiol and levonorgestrel is used primarily in hormone replacement therapy (HRT) and contraceptive formulations. Its market has experienced steady growth driven by demographic shifts, regulatory environments, and evolving clinical practices. The product's patent landscape, presence of generic alternatives, and regional health policies shape its commercial trajectory.

---

What Is the Current Market Size and Growth Trend?

The global market for combined estradiol and levonorgestrel products was valued at approximately $4.2 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.5% to 5.0% through 2030.

Key Drivers:

• Aging populations increasing demand for menopausal HRT.
• Rising contraceptive use among women of reproductive age.
• Increasing awareness and acceptance of hormone therapies.
• Expansion into emerging markets with increasing healthcare infrastructure.

Regional Breakdown (2022):

Region	Market share	Growth Rate (2022–2030)	Key Drivers
North America	45%	4.7%	High prevalence of menopausal women, contraceptive access
Europe	25%	4.8%	Aging population, well-established HRT markets
Asia-Pacific	15%	6.0%	Growing healthcare awareness, contraceptive adoption
Latin America	8%	4.2%	Increasing healthcare spending, demographic shifts
Middle East & Africa	7%	3.5%	Emerging markets, expanding access

---

What Are the Key Market Segments?

• Formulation Types: Pills (oral), patches, gels.
• Application: Contraception, menopausal hormone therapy, other hormonal disorders.
• End Users: Women of reproductive age (for contraception), menopausal women (HRT).

Oral pills dominate the market, accounting for approximately 70% of sales globally, owing to convenience and established clinical protocols. Patches and gels are gaining traction, particularly among patients with adherence challenges.

---

What Are the Main Competitive Dynamics?

Major Players:

• Bayer AG
• Teva Pharmaceutical Industries
• Mylan (now part of Viatris)
• Sandoz (Novartis)
• Pfizer

Market Share (2022):

Company	Estimated Market Share	Product Portfolio Highlights
Bayer	30%	Yaz, Yasmin, generic estradiol/levonorgestrel products
Teva	25%	Generic formulations, oral and patch formulations
Mylan / Viatris	20%	Generic contraceptives, HRT formulations
Sandoz	15%	Biogeneric versions, innovative delivery systems
Pfizer	10%	Established products, expanding biosimilar pipeline

Pricing Trends:

• Generic versions exert downward pressure, reducing prices by up to 50% over five years.
• Proprietary branded formulations maintain premium pricing, especially in markets with limited generic penetration.

Regulatory Influence:

• Stringent regulatory pathways in the US (FDA) and Europe (EMA) influence speed-to-market and patent protections.
• Data exclusivity and patent term extensions support profitability for branded drugs.

---

How Do Patent and Regulatory Landscapes Impact Market Trajectory?

Patent expirations typically occur 8–12 years post-launch, with many key formulations facing generic competition by 2022–2025, leading to revenue erosion for branded products.

Notable Patent Expiry Dates:

Product	Year of Patent Expiry	Impact
Estradiol/Levonorgestrel (Branded)	2022–2025	Market share shifts to generics, price declines

Regulatory Trends:

• The US FDA and EU EMA are increasingly requiring post-marketing surveillance for hormonal combinations due to safety concerns, possibly prolonging approval timelines for new formulations.
• The development of biosimilars and improved delivery systems (implants, transdermal) poses future competition.

---

What Are Key R&D and Innovation Trends?

• Transition from oral pills to transdermal patches and gels to improve compliance.
• Development of lower-dose formulations to minimize side effects.
• Integration with digital health for adherence monitoring.

Pipeline Developments:

• Limited pipeline of new molecular entities; most innovations focus on delivery systems and dosage forms.
• Filings of combination hormonal products with improved safety profiles are expected to increase in the next 3–5 years.

---

What Are the Potential Risks and Challenges?

• Regulatory hurdles delaying new product approvals.
• Increasing competition from generics and biosimilars.
• Safety concerns over hormonal therapies, including cardiovascular risks and breast cancer links.
• Market saturation in mature regions could slow revenue growth.

---

Financial Trajectory Outlook

Year	Estimated Revenue	Notes
2023	~$4.2 billion	Stable growth with generic price erosion
2025	~$4.4 billion	Patent expiries influence revenue stabilization
2030	~$6.3 billion	Growth driven by emerging markets and new formulations

Although growth slows post-patent expiration, expanding markets, especially in Asia-Pacific, contribute to overall revenue increase.

---

Key Takeaways

• The market for estradiol/levonorgestrel is growing modestly, driven mainly by menopausal HRT and contraception demand.
• Generic competition significantly influences pricing and profit margins.
• Emerging delivery systems and lower-dose formulations aim to capture future market share.
• Patent expiries and regulatory landscapes shape the competitive environment.
• The Philippine market, along with others in Asia-Pacific, offers substantial growth opportunities amidst expanding healthcare access.

---

5 FAQs

1. What is the main driver for growth in the estradiol/levonorgestrel market?
The primary driver is increasing demand for hormone replacement therapy among aging women and contraceptive use among reproductive-aged women, especially in emerging economies.

2. How does patent expiration affect market revenue?
Patent expirations open the market to generic versions, leading to significant price reductions and revenue decline for branded products. This effect is evident from 2022–2025.

3. What are the leading formulations in this market?
Oral pills dominate, with patches and gels gaining popularity for their convenience and improved adherence.

4. Which regions are expected to see the fastest growth?
Asia-Pacific exhibits the highest CAGR (~6%), driven by expanding healthcare infrastructure and increasing contraceptive and HRT demand.

5. What future innovations could influence the market?
Development of transdermal patches, lower-dose formulations, and integration with digital health monitoring software are expected to shape future offerings.

---

Cited Sources

[1] Market Research Future. "Global Contraceptive Devices Market Research Report." 2022.
[2] Grand View Research. "Hormone Replacement Therapy Market Size, Share & Trends Analysis." 2023.
[3] IQVIA. "Pharmaceutical Market Data and Insights." 2023.
[4] European Medicines Agency. "Hormonal Contraceptives and HRT Regulatory Updates." 2023.
[5] FDA. "Updated Guidance on Hormonal Contraceptives." 2022.